A thymoma is a slow-growing tumor that arises from the epithelial cells of the thymus, a small gland situated behind the breastbone in the upper chest. With an overall incidence of roughly 0.13 per 100,000 person-years in the United States, it ranks among the rarest solid tumors, yet it is the most common tumor of the anterior mediastinum in adults. What makes thymoma unusual compared with most cancers is its deep entanglement with the immune system: the thymus is where the body trains its T cells, and when a tumor disrupts that process, the consequences can ripple far beyond the chest.
What the Thymus Does and Why Tumors There Matter
The thymus is a primary lymphoid organ responsible for developing T lymphocytes, the white blood cells that coordinate the body’s adaptive immune response. Immature immune cell precursors migrate into the thymus, pass through a series of checkpoints in its outer (cortical) and inner (medullary) regions, and emerge as functional T cells capable of recognizing a huge range of pathogens while ignoring the body’s own tissues.1PubMed Central. The Role of the Thymus in the Immune Response Stromal cells within the thymus provide essential signals that guide each stage of this maturation.2PubMed. Microenvironmental regulation of T cell development in the thymus When a thymoma grows inside this gland, it can corrupt the selection process, releasing self-reactive T cells or antibodies that attack the body’s own tissues. That is why thymomas are so strongly linked to autoimmune conditions, a feature that shapes nearly every aspect of diagnosis, treatment, and follow-up.
How Common Is Thymoma and Who Gets It
Thymoma is exceedingly rare in children and young adults, rises through middle age, and peaks in the seventh decade of life. US cancer registry data show the highest age-specific incidence at roughly 0.68 per 100,000 in the 70-to-79-year-old bracket.3PubMed Central. Epidemiology of thymoma and associated malignancies Incidence is especially elevated among Asian and Pacific Islander populations in the US, and trend data suggest it has been rising modestly in white women.4PLoS ONE. Trends in the incidence of thymoma, thymic carcinoma, and thymic neuroendocrine tumor in the United States In the pediatric population, thymomas are much rarer still, slightly more frequent in boys, and less commonly accompanied by myasthenia gravis than adult cases.5PubMed Central. Pediatric Thymoma: A Review and Update of the Literature
Symptoms and How Thymomas Are Found
About 30 percent of people with a thymoma have no symptoms at all; the tumor turns up incidentally on a chest X-ray or CT scan ordered for something else.6PubMed Central. When to suspect a thymoma: clinical point of view When symptoms do appear, they generally fall into two categories. Local symptoms stem from the tumor pressing on nearby structures: a persistent cough, chest pain, hoarseness, or difficulty breathing. The second, more distinctive category involves paraneoplastic disorders, where the tumor triggers the immune system to attack normal tissues elsewhere in the body. These autoimmune complications are often the first clue that something is wrong, and they can appear months or even years before the thymoma itself is detected.
The Myasthenia Gravis Connection
The most recognized autoimmune link is myasthenia gravis, a condition in which antibodies attack the receptors at the junction between nerves and muscles, causing fluctuating muscle weakness. About half of people with cortical-type thymomas develop myasthenia gravis, and roughly 15 percent of myasthenia gravis patients turn out to harbor a thymoma.7PubMed Central. Thymoma in myasthenia gravis: from diagnosis to treatment The relationship runs deep enough that anyone newly diagnosed with myasthenia gravis will typically get a chest CT scan to rule out a thymoma, and discovering a thymoma often prompts testing for myasthenia gravis even when muscle symptoms are subtle.
Thymectomy, the surgical removal of the thymus, is itself a recognized treatment for myasthenia gravis regardless of whether a thymoma is present. In one series of patients followed for five years after thymectomy, about 8 percent achieved complete stable remission, meaning they came off all medication and remained symptom-free.8Journal of Thoracic and Cardiovascular Surgery. Five-year clinical outcomes and remission rates after thymectomy in patients with myasthenia gravis A separate 10-year review reported an overall improvement or remission rate of about 87 percent, though complete remission was less common.9PubMed Central. Thymectomy for Myasthenia Gravis: A 10-year Review of Cases at the Hospital Universiti Sains Malaysia These numbers illustrate that while thymectomy helps most myasthenia gravis patients to some degree, a complete cure where all immunosuppressive drugs can be stopped remains the exception rather than the rule.
Other Autoimmune and Paraneoplastic Conditions
Myasthenia gravis gets the headlines, but roughly 40 percent of thymomas are associated with one or more paraneoplastic syndromes, and the list is long.10The Annals of Thoracic Surgery. Thymoma With Pure Red Cell Aplasia and Good’s Syndrome Pure red cell aplasia, a condition where the bone marrow stops producing red blood cells, is one of the more serious ones. Good syndrome, an immunodeficiency marked by very low levels of circulating antibodies, leaves patients vulnerable to infections that healthy adults would shrug off. These conditions are rarer than myasthenia gravis but can appear together, sometimes alongside additional autoimmune organ damage, creating clinical pictures that are genuinely challenging to manage.11PubMed Central. Pure Red Cell Aplasia Associated with Good Syndrome Case reports describe patients presenting with all three simultaneously.12Respiratory Medicine Case Reports. A case of synchronous triple autoimmune disorders secondary to thymoma: Pure red cell aplasia, Good’s syndrome, and thymoma-associated multi-organ autoimmunity
One frustrating aspect of these paraneoplastic syndromes is that removing the thymoma does not always resolve them. Some patients see dramatic improvement after surgery; others need prolonged immunosuppressive therapy; still others remain dependent on treatments like intravenous immunoglobulin or blood transfusions indefinitely. Predicting who will respond and who will not remains an open problem.
Thymoma Types and How They Are Classified
Thymomas are categorized under the World Health Organization system into several histological types, labeled A, AB, and B1 through B3, with progressively more aggressive behavior as you move along the spectrum. The 2015 WHO classification refined the diagnostic criteria for each type and separated thymomas from thymic carcinomas, which behave like a different disease entirely.13PubMed Central. The 2015 World Health Organization Classification of Tumors of the Thymus: Continuity and Changes Genomic profiling work has confirmed that these categories are not purely cosmetic: type B3 thymomas and thymic carcinomas cluster together molecularly and apart from types A and B2, and thymic carcinomas carry mutations (particularly in the KIT gene) that thymomas typically do not.14PubMed. Thymoma versus thymic carcinoma: differences in biology impacting treatment
This distinction matters because thymoma and thymic carcinoma, despite both originating in the thymus, differ in behavior, treatment response, and outlook. Thymomas tend to grow slowly and stay encapsulated for years. Thymic carcinomas are more aggressive, metastasize earlier, and are less likely to be associated with autoimmune conditions. Lumping them together, as older literature sometimes did, can be misleading.
Staging and What It Means for Treatment
Thymoma staging has historically relied on the Masaoka-Koga system, which focuses on how far the tumor has invaded surrounding structures. In 2017, a formal TNM-based staging system was introduced, developed jointly by international thoracic oncology groups. The newer system shifts certain involvements that surgeons can handle cleanly, such as tumor touching the pericardium, mediastinal fat, or mediastinal pleura, into lower stages. The practical effect is that tumors are divided more cleanly into those that can be completely removed surgically (stages I through IIIA) and those requiring additional treatment modalities (stages IIIB and beyond).15PubMed Central. Classification and staging of thymoma When researchers compared the two systems directly, all Masaoka-Koga stage II patients were reclassified as TNM stage I, while the proportion of patients in the highest stages remained similar between the two frameworks.16PubMed Central. Impact of the TNM staging system for thymoma
Surgery as the Cornerstone of Treatment
Complete surgical removal is the primary treatment for thymoma whenever feasible, and for early-stage disease it is often the only treatment needed. The traditional approach has been a median sternotomy, where the breastbone is split down the middle for full access to the mediastinum. Over the past two decades, minimally invasive approaches have gained ground. A systematic review comparing robotic thymectomy with open surgery found that the robotic approach resulted in less blood loss, fewer postoperative complications, shorter hospital stays, and a lower rate of positive surgical margins, with operating times that were statistically comparable.17PubMed Central. A systematic review of robotic versus open and video assisted thoracoscopic surgery (VATS) approaches for thymectomy Robotic and video-assisted thoracoscopic approaches performed similarly to each other and both avoided the need for sternotomy.
Quality of life comparisons reinforce the minimally invasive edge. Patients who had video-assisted surgery reported better general health, less pain, and more positive self-assessments of physical activity compared with those who had sternotomy for early-stage disease.18Journal of Thoracic Oncology. Does Surgical Incision Affect Quality of Life in Masaoka Stage 1-2 Thymomas? That said, minimally invasive surgery is not appropriate for every case; large tumors or those invading major blood vessels still require an open approach to achieve complete removal safely.
Radiation and Chemotherapy
Whether radiation therapy is needed after surgery depends heavily on stage and whether the surgeon achieved clear margins. For completely resected stage I thymoma with negative margins, surveillance alone is standard and postoperative radiation can be safely skipped. For invasive stage III disease, postoperative radiation is considered standard practice. It is also recommended for any case with residual tumor at the margins and for virtually all thymic carcinomas beyond stage I.19PubMed Central. Role of radiotherapy in thymoma and thymic carcinoma: a narrative review The gray zone is stage II disease, where the decision often depends on the tumor’s histological subtype and whether the margins are truly clean.20The Annals of Thoracic Surgery. The Role of Adjuvant Radiation Therapy for Resected Stage III Thymoma: A Population-Based Study
For advanced or unresectable disease, chemotherapy enters the picture. Cisplatin-based and anthracycline-based regimens are considered the standard of care. Carboplatin paired with paclitaxel is a widely used alternative, especially for patients who cannot tolerate cisplatin or anthracyclines.21PubMed. Therapeutic management of patients with advanced thymic malignancies: A review for clinicians In one study, a neoadjuvant combination of cisplatin, doxorubicin, and methylprednisolone produced partial or complete responses in over 90 percent of patients with advanced invasive thymoma, shrinking tumors enough to allow surgical resection.22Journal of Thoracic Oncology. Multidisciplinary Treatment for Advanced Invasive Thymoma with Cisplatin, Doxorubicin, and Methylprednisolone The goal of this kind of induction chemotherapy is to convert an initially inoperable tumor into one that can be removed.
Why Immunotherapy Is Complicated for Thymoma
Immune checkpoint inhibitors have transformed the treatment of many cancers, but thymomas present a paradox. Because the thymus is the training ground for immune cells, disrupting its tolerance machinery with drugs that unleash the immune system can trigger autoimmune side effects at rates far exceeding what oncologists see with other tumor types. Adverse-event reports to the FDA show that patients with thymic tumors treated with immunotherapy experience muscle inflammation, heart inflammation, and myasthenia gravis at disproportionately high rates compared to other cancer patients on the same drugs.23PubMed Central. Immunotherapy Safety in Thymic Epithelial Tumors: Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System
Thymomas, specifically, carry higher autoimmune risk than thymic carcinomas when exposed to checkpoint blockade, which is somewhat ironic given that thymic carcinomas are the subtype more likely to show objective tumor shrinkage in response to these drugs.24PubMed. Fatal toxicity induced by anti-PD-1 immune checkpoint inhibitor in thymic epithelial tumor Clinical studies of immune checkpoint blockade in both thymoma and thymic carcinoma have shown higher frequencies of immune-related adverse events and limited efficacy overall.25PubMed. Understanding the landscape of immunotherapy in thymic epithelial tumors The result is that immunotherapy remains a cautious, case-by-case decision for thymic tumors rather than the standard-of-care role it occupies in lung cancer or melanoma.
Targeted Therapies for Thymic Carcinoma
While thymomas are generally treated with conventional surgery, radiation, and chemotherapy, thymic carcinomas have drawn interest from the targeted therapy world. Some thymic carcinomas carry KIT gene mutations, and although these mutations are not common, the tumors that do have them can respond to drugs originally developed for other KIT-driven cancers. In one study, the multitarget inhibitor sunitinib produced a partial response in about a quarter of thymic carcinoma patients, with disease control achieved in over 90 percent.26PubMed Central. Insights into molecular aspects and targeted therapy of thymic carcinoma: a narrative review These numbers are encouraging for a tumor with limited options after first-line chemotherapy, though the rarity of thymic carcinoma means that large confirmatory trials are difficult to run.
Recurrence and the Case for Lifelong Follow-Up
Thymomas have a well-known tendency to recur years or even decades after initial treatment, which distinguishes them from most cancers where the danger window is concentrated in the first few years. The most common site of recurrence or metastasis is the pleura, the lining around the lungs, followed by the lung itself and thoracic lymph nodes.27PubMed Central. Patterns of metastasis and recurrence in thymic epithelial tumours: longitudinal imaging review in correlation with histological subtypes The timeline depends on tumor aggressiveness: thymic carcinomas that recur tend to do so within the first three years, while low-risk thymomas can recur much later, with median times stretching well beyond five years. In one surgical series, the latest recurrence appeared nearly eight years after the original operation, leading the authors to advocate for prolonged, if not lifelong, surveillance.28The Journal of Thoracic and Cardiovascular Surgery. Comparison of outcomes and patterns of recurrence in thymic carcinoma and thymoma
This means that even after a successful operation with clear margins, most experts recommend ongoing imaging, typically annual chest CT scans, for many years. The follow-up interval may be tighter in the early postoperative period for higher-risk subtypes or incomplete resections. The upside of this vigilance is that recurrent thymomas, because they tend to grow slowly, can often be treated again with surgery, radiation, or both, sometimes more than once over a patient’s lifetime.
Long-Term Quality of Life After Treatment
For a disease that can require sternotomy, radiation, chemotherapy, and years of surveillance, the quality-of-life picture is surprisingly reassuring. A study of 72 survivors of thymic malignancies found that most reported minimal symptoms and favorable health-related quality of life, with the most common complaints being mild fatigue, some shortness of breath, and a general sense of reduced wellbeing, all rated as mild on standardized scales. Patients who had received aggressive multimodal therapy, combining surgery with radiation and chemotherapy, reported quality-of-life scores that were statistically similar to those who had been treated with surgery alone.29European Journal of Cardio-Thoracic Surgery. Favourable health-related quality of life reported in survivors of thymic malignancies Even among patients whose disease had recurred and required additional treatment, quality-of-life scores did not differ significantly from those who remained disease-free. This is encouraging, though it likely reflects the slow-growing nature of most thymomas and the relatively young and otherwise healthy population that tends to develop them.